BioCore Dairy (Lactase blend)

BioCore Dairy is a proprietary lactase enzyme blend that hydrolyzes lactose into its monosaccharide components, glucose and galactose, enabling lactose-intolerant individuals to digest dairy without discomfort. It also contains proteases specifically targeting casein and beta-lactoglobulin, the dominant proteins in cow's milk.

Origin & History

BioCore Dairy is a branded enzyme blend produced by National Enzyme Company that combines lactase with proteases and lipase to support dairy digestion. The lactase enzyme is derived from fungal sources, specifically Aspergillus oryzae, and works synergistically with additional enzymes to break down lactose, milk proteins (casein and beta-lactoglobulin), and milk fats.

Historical & Cultural Context

The research provides no information about historical use of lactase enzyme blends in traditional medicine. Lactase supplementation is described as a modern pharmaceutical and nutraceutical approach developed in response to scientific understanding of lactose intolerance in the 20th century.

Health Benefits

• Breaks down lactose into glucose and galactose for improved dairy digestion (mechanism established, no clinical trials provided in research)
• Supports digestion of milk proteins through protease activity targeting casein and beta-lactoglobulin (mechanism described, no clinical evidence provided)
• Assists with milk fat digestion via lipase enzyme activity (theoretical benefit, no clinical studies available)
• May reduce bloating and discomfort from lactose fermentation in the colon (mechanism-based claim, no specific trials cited)
• Provides broad pH range activity (2-8) for function throughout digestive tract (product characteristic, no clinical outcomes documented)

How It Works

BioCore Dairy's lactase component (beta-galactosidase) cleaves the glycosidic bond between glucose and galactose in lactose, preventing undigested lactose from reaching the colon where bacterial fermentation causes bloating and gas. Its protease fraction targets casein micelles and the whey protein beta-lactoglobulin, hydrolyzing peptide bonds to reduce immunoreactive fragments and improve protein absorption. These enzymatic actions occur in the small intestinal lumen, functioning optimally at the acidic-to-neutral pH range encountered during gastric emptying.

Scientific Research

The research dossier contains no peer-reviewed clinical trials, randomized controlled trials, meta-analyses, or PubMed PMIDs evaluating BioCore Dairy specifically. While the product's intended mechanism and use in commercial formulations are described, no human clinical studies with specific sample sizes, study designs, or quantified outcomes are documented in the provided sources.

Clinical Summary

No published clinical trials specific to the BioCore Dairy blend were identified in the available research. However, the underlying enzyme classes have established mechanistic evidence: lactase supplementation broadly has been studied in randomized controlled trials showing reductions in bloating, flatulence, and diarrhea in lactose-intolerant subjects consuming dairy. The protease activity targeting casein and beta-lactoglobulin is mechanistically described but lacks proprietary clinical outcome data quantifying its effect on digestive comfort or protein bioavailability. Independent controlled trials with defined dosing of this specific blend are needed to substantiate efficacy claims beyond the known activity of its constituent enzyme classes.

Nutritional Profile

BioCore Dairy is a multi-enzyme blend complex, not a nutritional ingredient in the traditional macronutrient sense. It contributes negligible calories, protein, fat, or carbohydrates at functional dosages (typically 100–500 mg per serving). The blend is composed of several enzymatic protein complexes: Lactase (beta-galactosidase, typically 3,000–9,000 ALU per serving) derived from Aspergillus oryzae, which catalytically cleaves lactose into glucose and galactose; Protease enzymes (targeting casein and beta-lactoglobulin, measured in HUT/AP/SAPU units) sourced from fungal or microbial fermentation origins; and Lipase (measured in FCCLU or LU units) to assist triglyceride hydrolysis from milk fats. Bioactive compounds include the enzyme proteins themselves, which are biologically active at trace concentrations but are denatured and inactivated in the stomach when not enteric-coated, limiting systemic bioavailability. No significant vitamins or minerals are contributed by the blend itself. Bioavailability of the enzymatic activity is pH-dependent; lactase from Aspergillus oryzae retains activity at gastric pH 3.5–5.5, offering an advantage over mammalian-derived lactase. Enzyme cofactors such as trace calcium ions may be present from fermentation substrates at sub-milligram levels. No fiber content. The blend is standardized by enzymatic activity units rather than by weight concentration of individual proteins.

Preparation & Dosage

Formulations vary in potency: one product provides 14,690 HUT of protease, 2,545 DU of amylase, and 727 ALU of lactase per capsule. Another formulation references 4,500 FCC LU (Lactase Units) per capsule. No standardized clinical dosage ranges for BioCore Dairy as a standalone product are provided in the research. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Probiotics, Prebiotics, Digestive Bitters, Ginger Extract, Peppermint Oil

Safety & Interactions

Lactase and digestive protease supplements are generally recognized as safe with minimal reported adverse effects at standard supplemental doses. Individuals with galactosemia should avoid lactase supplements, as hydrolysis of lactose liberates galactose, which cannot be properly metabolized in this condition. No significant drug interactions with lactase blends are well-documented, though those on alpha-glucosidase inhibitors such as acarbose should consult a physician, as complementary carbohydrate-metabolizing enzyme activity may theoretically alter glycemic response. Safety data for BioCore Dairy specifically during pregnancy or breastfeeding has not been established, and consultation with a healthcare provider is recommended.